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ABSTRACT: The analysis of intact glycopeptides by mass
spectrometry is challenging due to the numerous possibilities for
isomerization, both within the attached glycan and the location
of the modification on the peptide backbone. Here, we
demonstrate that high field asymmetric wave ion mobility
spectrometry (FAIMS), also known as differential ion mobility, is
able to separate isomeric O-linked glycopeptides that have
identical sequences but differing sites of glycosylation. Two
glycopeptides from the glycoprotein mucin 5AC, GT(GalNAc)-
TPSPVPTTSTTSAP and GTTPSPVPTTST(GalNAc)TSAP
(where GalNAc is O-linked N-acetylgalactosamine), were shown to coelute following reversed-phase liquid chromatography.
However, FAIMS analysis of the glycopeptides revealed that the compensation voltage ranges in which the peptides were
transmitted differed. Thus, it is possible at certain compensation voltages to completely separate the glycopeptides. Separation of
the glycopeptides was confirmed by unique reporter ions produced by supplemental activation electron transfer dissociation mass
spectrometry. These fragments also enable localization of the site of glycosylation. The results suggest that glycan position plays a
key role in determining gas-phase glycopeptide structure and have implications for the application of FAIMS in glycoproteomics.
G
lycosylation of proteins is the most common post-
translational modification in eukaryotic cells: It has been
estimated that up to 50% of human proteins are glycosylated.
1
Glycoproteins are involved in a range of intracellular and cell−
cell recognition events,
2,3 and abnormalities in glycosylation are
associated with disease. For example, a decrease in O-linked
glycosylation of microtubule-associated protein tau has been
shown in patients with Alzheimer’s disease.
4 Similarly, aberrant
glycosylation of IgA1 is implicated in IgA nephropathy.
5
Proteins are glycosylated at either asparagine (N-linked) or
serine, threonine, and tyrosine residues (O-linked). N-
glycosylation occurs within the consensus sequence Asn-X-
Ser/Thr, where X is any amino acid except Pro, whereas no
consensus sequence exists for O-glycosylation. Glycoproteo-
mics is the large scale analysis of glycoproteins and typically
involves digestion of the proteins with trypsin and analysis of
the resulting glycopeptides.
6 There is enormous scope for
isomers within the glycopeptides: Due to the numerous
possible combinations of different monosaccharide base units,
glycosylation is one of the most complex post-translational
modifications.
7 It is possible to have both structural and
positional isomers, i.e., glycans that differ in glycosidic linkage
arrangements and in branching structures. In addition, and
particularly for O-glycosylation, there is the potential for
localization isomers, i.e., glycopeptides with identical sequences
but differing modification sites.
Glycosylation has been studied by mass spectrometry for
many years but the assignment and localization of glycans on
glycopeptides remains a challenge. Typically, the proteomics
workflow involves online liquid chromatography coupled with
tandem mass spectrometry (MS/MS). The MS/MS technique
collision induced dissociation (CID) results in loss of the
glycan while the peptide backbone remains intact,
6 hindering
the identification of both the peptide sequence and the site of
glycosylation. Electron capture dissociation and electron
transfer dissociation (ETD) of glycopeptides results in
retention of the glycan chain on the peptide backbone
fragments, allowing localization of the modification site.
8−11
However, glycans are acidic modifications, and glycosylated
peptides are commonly only observed as singly, doubly, or
triply charged ions with high m/z values. These types of ions
often produce ETD spectra with few fragment ions.
12 Recently,
several methods have been developed which combine CID and
ETD to better determine the sequence of glycopeptides.
13−15
Nevertheless, these various methods do not address the
underlying issue of isomeric glycopeptides which coelute
following liquid chromatography.
High field asymmetric wave ion mobility spectrometry
16,17
(FAIMS), or differential ion mobility, separates gas-phase ions
at atmospheric pressure. Ions are transferred between two
heated electrodes by a carrier gas. Voltages are applied to the
electrodes via an asymmetric waveform producing alternate
high and low electric fields perpendicular to the direction of the
ions. As a result of their differential mobility, ions are attracted
toward one of the electrodes to a greater extent than the other.
In the absence of intervention, the ions will collide with the
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voltage (CV) is superimposed. By tuning the CV, it is possible
to selectively transmit particular ions through the FAIMS
device into the mass spectrometer. The FAIMS device can
therefore be used as an ion filter, effectively reducing signal-to-
noise,
18 increasing sensitivity,
19,20 and increasing dynamic
range.
21
As FAIMS separates ions according to their differential ion
mobility, rather than m/z, it may be applied for the analysis of
isobaric species: The amino acids leucine and isoleucine can be
separated by FAIMS,
22 as can the ortho, meta, and para forms
of phthalic acid.
23 We have shown previously that FAIMS can
separate isobaric phosphopeptides, i.e., those with identical
sequence but differing sites of phosphorylation.
24,25 In further
work, we have shown that FAIMS may be used to separate
sequence isomers of nitrated peptides.
26 Fenn and McLean
have separated structural and positional isomeric glycans
27 by
drift tube ion mobility spectrometry and traveling wave ion
mobility spectrometry; however, to date, there have been no
reports of ion mobility separation of intact glycopeptides.
Here, we demonstrate FAIMS separation of two glycopep-
tide localization isomers from the glycoprotein mucin 5AC:
GT(GalNAc)TPSPVPTTSTTSAP and GTTPSPVPTTST-
(GalNAc)TSAP, where GalNAc is O-linked N-acetylgalactos-
amine. These glycopeptides coelute following reversed-phase
liquid chromatography. FAIMS separation was confirmed by
supplemental activation (sa) ETD mass spectrometry. As the
differential ion mobility of an ion is intrinsically linked to its
structure, our finding suggests that the position of the glycan
affects the gas-phase structure of the glycopeptides. Our
findings have implications for the field of glycoproteomics:
The ability to separate isomeric glycopeptides will further
enable identification of isoforms and ultimately improve
glycoproteome coverage.
■ METHODS
Sample Preparation. The glycopeptides from Mucin 5AC
with the sequences, GTTPSPVPTTSTTSAP and
GTTPSPVPTTSTTSAP (where T represents the threonine
amino acid residue modified with N-acetylgalactosamine,
GalNAc), herein referred to as peptides A and B, respectively,
were supplied by Anaspec (Fremont, CA) and used without
further purification. For the LC-ETD MS/MS experiments, the
samples were resuspended in water (J. T. Baker, The
Netherlands) to a final concentration of 20 fmol/μL. For the
FAIMS experiments, the samples were resuspended in water
a n dd i l u t e di nw a t e r / m e t h a n o l( b o t hJ .T .B a k e r ,T h e
Netherlands) (30:70) containing 2% formic acid (Sigma
Aldrich, Poole, Dorset), to a final concentration of 2 pmol/μL.
LC-ETD MS/MS. Online liquid chromatography was
performed by use of a Dionex Ultimate 3000 HPLC system
(Sunnyvale, USA). A 1:1 mixture comprising 100 fmol of each
peptide was loaded onto a 75 μm (internal diameter) Acclaim
PepMap100 (LC Packings, Sunnyvale, USA) C18 column
(length 10 cm) and separated over a 30 min gradient from 3.2%
to 44% acetonitrile (J. T. Baker, The Netherlands) (0.1%
formic acid) at a flow rate of 350 nL/min. Eluting peptides
were infused by use of an Advion Triversa Nanomate (Ithaca,
USA) electrospray ionization source directly into a Thermo
Scientific LTQ-Orbitrap Velos ETD mass spectrometer (Bre-
men, Germany). The mass spectrometer alternated between a
full FT-MS scan (m/z 380−1600) and a sa ETD scan
(conditions as below) of the most abundant precursor ion.
Survey scans were acquired in the Orbitrap with a resolution of
60 000 at m/z 400. Precursor ions were isolated and subjected
to ETD in the linear ion trap and recorded in the Orbitrap at a
resolution of 7500 at m/z 400. Isolation width was 3 Th.
Automatic gain control (AGC) was used to accumulate
sufficient precursor ions (target value 1 × 105 charges,
maximum fill time 100 ms). Dynamic exclusion was not used.
Figure 1. The extracted ion chromatograms for the doubly charged precursor ion m/z 852.91 (black), fragment c10 (red) from the glycopeptide
GTTPSPVPTTSTTSAP, and fragment z10 (blue) from the glycopeptide GTTPSPVPTTSTTSAP. T represents the threonine amino acid residue
modified with N-acetylgalactosamine, GalNAc.
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into the mass spectrometer by direct infusion heated
electrospray ionization (HESI) at a flow rate of 3 μL/min
and a temperature of 40 °C. All FAIMS experiments were
performed on an LTQ Orbitrap Velos ETD hybrid mass
spectrometer (Thermo Fisher Scientific, Bremen, Germany).
The FAIMS conditions were: dispersion voltage, −5 kV; inner
and outer electrode temperatures, 70 and 90 °C, respectively;
carrier gas flow rate, 2 L/min with a composition of 50:50
helium to nitrogen. The electrospray voltage was 5 kV with a
capillary temperature of 275 °C and a sheath gas flow rate of 5
L/min. During analysis, the compensation voltage was scanned
from −59.7 to −5 V in 0.3 V steps. The precursor ion of
interest was fragmented by supplemental activation ETD at
each CV interval, resulting in 180 saETD spectra. All mass
spectra were acquired in the Orbitrap. An automated method
was created: The first scan event was a full scan mass spectrum
at CV of −25 V. This was followed by 180 sa ETD mass spectra
of the doubly charged precursor (m/z 852.91) with CV
scanning as described above. The automatic gain control
(AGC) target for full scan and subsequent MS/MS spectra was
1 × 106, with a maximum injection time of 1000 ms for MS
spectra and 300 ms for MS/MS spectra. Both MS and MS/MS
scans were recorded with a resolution of 7500 at m/z 400. MS
spectra were the result of 1 microscan, and MS/MS were 5
summed microscans. Precursor ions were isolated with a
window of 3 Th. Supplemental activation (sa) ETD was
performed in the ion trap, with an ETD activation time of 140
ms and a normalized collision energy (sa) of 25%.
■ RESULTS AND DISCUSSION
A 1:1 mixture of the two glycopeptides were analyzed by online
liquid chromatography saETD MS/MS. Figure 1 shows the
extracted ion chromatograms of the doubly charged precursor
(m/z 852.91; black) and the reporter ions c10 from
glycopeptide A (m/z 1158.58; red) and z10 from glycopeptide
B (m/z 1149.55; blue). Reporter ions are those ETD fragments
which are unique to a particular modification site within a
peptide. These results show that it is not possible to separate
these glycopeptides by reversed-phase liquid chromatography.
The glycopeptides were individually infused and analyzed by
FAIMS-saETD to assess the level of fragmentation observed,
the potential number of unique reporter ions, and the CV range
over which the peptides were transmitted. As the reporter ions
are unique to a particular modification site within a peptide,
their presence can be used to confirm the success, or otherwise,
of FAIMS separation.
25 For both glycopeptides A and B, singly
and doubly charged ions were observed. Doubly charged
glycopeptide ions were subjected to saETD. Figure 2a shows
the saETD spectrum for peptide A recorded with at a CV of
−23.7 V, approximately the midpoint in the CV range over
which the doubly charged peptide was observed. All but three
N−Cα bonds were cleaved. (Cleavage N-terminal to proline is
rare due to the cyclic nature of the side chain.
28) Two peaks
(m/z 1501.73 and m/z 1328.62) in the spectrum show the loss
of the GalNAc from the peptide backbone: [M + 2H-
GalNAc]+￿ and z14-GalNAc. No other neutral losses of GalNAc
were observed. The probable cause of the losses of the glycan is
the use of supplemental activation with the ETD. Similarly, the
presence of the y9 ion may be the result of supplemental
activation, although production of y ions is known to be a
Figure 2. (a) Supplemental activation ETD mass spectrum of [M + 2H]2+ ions of peptide A, recorded at a CV of −23.7 V. (b) Supplemental
activation ETD mass spectrum of [M + 2H]2+ ions of peptide B, recorded at a CV of −25.5 V. The CV values represent the maximum transmission
of the precursor ions through the FAIMS device.
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c8 − c12, z12, and y9 may be used as reporter ions for peptide A.
The saETD spectrum for peptide B is shown in figure 2b. The
spectrum was recorded at a CV of −25.5 V, the approximate
midpoint of the CV range over which the doubly charged
peptide was observed. The fragmentation pattern observed is
nearly identical to that seen for peptide A; the only differences
being the absence of the c6 fragment (m/z 558.29) and the
presence of a peak corresponding to z10-GalNAc (m/z 946.46).
These results suggest that the fragment ions c8 − c12, z10, z12,
and y9 may be used as reporter ions for peptide B.
The glycopeptides were combined in a 1:1 mixture and
analyzed using the same method as above. The peptides
“eluted” from the FAIMS device in the compensation voltage
range of −29.7 V to −19.5 V, and ETD reporter ions were
observed in the CV range of −29.1 V and −19.8 V. (At CV
points −29.7, −29.4, and −19.5 V, the ETD mass spectra
contained peaks corresponding to the charge-reduced species
and the more abundant fragments common to both
glycopeptides only.) Figure 3a shows the extracted ion
chromatograms for seven of the reporter ions for peptide B
(fragments c8, c9, c10, c11, c12, z10, and z12, shown in blue) and
five of the reporter ions for peptide A (fragments c8, c9, c10, c11,
and c12, shown in red). The additional reporter ions for peptide
A (c6 and z12) and the y9 fragments for both peptides are not
shown here because they were not observed in every spectrum.
The overlaid extracted ion chromatograms of the reporter ions
for the two glycopeptides (Figure 3a) show compensation
voltage ranges where (a) only peptide B is observed (−29.1 to
−27.3 V), (b) both glycopeptides are observed (−27.0 to
−20.7 V), and (c) only peptide A is observed (−20.4 to −19.8
V). Figure 3b shows the saETD mass spectrum obtained at CV
of −27.6 V. All of the fragments in this mass spectrum originate
from glycopeptide B. Figure 3c shows the saETD spectrum
recorded at CV −20.7 V. All the fragments in this mass
spectrum derive from glycopeptide A.
As FAIMS separates ions on the basis of their differential ion
mobility, which in turn is linked to ion structure, these findings
suggest that glycopeptides have gas-phase structures dependent
on the site of glycosylation. The glycopeptides studied here are
modified by a single GalNAc unit. It is possible that steric
hindrance gives rise to differing gas-phase structures. An
alternative explanation for the separation of the two
glycopeptides by FAIMS is the presence of salt bridges
between a carboxylate of the GalNAc and the amine group of
the N-terminus.
29,30 We postulate that such a salt-bridge would
only be present in glycopeptide B, giving the peptide a more
compact structure, and that the proximity of the GalNAc on
peptide A to the N-terminus and the lack of other potential
binding sites would hinder the formation of such a noncovalent
bond.
■ CONCLUSION
We have shown that it is possible to use FAIMS to separate
localization isomers of O-linked glycopeptides and confirmed
the separation by saETD mass spectrometry. Glycosylation is
unlike any other post-translational modification. The complex-
ity and heterogeneity of glycosylation can have a dramatic effect
on the structure and folding of peptides and proteins.
31 Our
results suggest that structural differences can also be observed
in the gas phase and that those differences can be exploited for
Figure 3. (a) Extracted ion chromatograms for the reporter c and z ions of peptide A (c8, c9, c10, c11, and c12, red) and peptide B (c8, c9, c10, c11, c12, z10,
and z12, blue). (b) Supplemental activation ETD mass spectrum recorded at a CV of −27.6 V. Reporter ions for peptide B are labeled in blue. (c)
Supplemental activation ETD mass spectrum recorded at a CV of −20.7 V. Reporter ions for peptide A are labeled in red.
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